areas where the condition is common, by lack of uniformity of diagnostic criteria, or by differing stages of presentation of the disease34. The different prevalences of the protein in primary hepatocellular cancer in Caucasians and Negroes in the United States of America 14,30 suggests that ethnic factors may also play a role in determining its occurrence. Experimental work has shown that the frequency with which AFP is found in animal hepatoma is probably not related to the chemical agent used to induce malignancy 35. Persistence of the hepatitis-B antigen (HBAg) has recently been incriminated as a cause of primary hepatocellular cancer36, and the possibility has been raised that the hepatitis virus may derepress the AFP genome as part of its oncogenic potential. The prevalence of the HBAg carrier state does vary in different parts of the world, but in three recent studies no correlation could be demonstrated between hepatitis-B antigenaemia and the presence of AFP in patients with primary hepatocellular 1acr7,37,38 There is no obvious correlation between the serum AFP level in human primary hepatocellular cancer and any of the clinical or biochemical parameters of the disease, the size and stage of the tumour, or survival time after diagnosis8" 3'33 . Attempts to relate the degree of differentiation of the tumour to the presence of the globulin have produced conflicting results6 8" '-'3"7'39 .
In striving both to decrease the number of 'false-negative' results, and to make earlier diagnosis of primary hepatocellular cancer possible, more sensitive methods for detecting the protein have been introduced, to the pointwhere normal levels can now be detected. While the former objective has been realized there has inevitably been a lessening of the specificity of the test. Using radioimmunoassay, Ishii40 has been able to increase the AFP-positivity rate in Chinese patients with primary hepatocellular cancer to 93 % compared with 69% by the immunodiffusion method. With a somewhat less sensitive technique, McIntire et a141 increased the number of positive results in Ugandan patients from 71 to 93 %. Purves42 has shown that the AFP concentration falls within the normal adult range in less than 1 % of primary liver tumours in South African Negroes. However, in other series the use of the newer methods has not significantly improved the positivity rate43. Thus, even with the most sensitive techniques, it appears that in some patients primary hepatocellular cancer is not associated with AFP production. Synthesis of the globulin is therefore not essential for oncogenesis, or at least not for the maintenance of the neoplastic state.
Cumulative Several authorities in this field have recently stressed the need to go beyond simply reporting the serum AFP as being positive or negative, and to study the dynamics of the protein as a biochemical marker of disease activity in patients with primary hepatocellular cancer and germinal cell cancers of the gonads. Unlike the situation in experimental animals, production of AFP by human primary hepatocellular cancer appears to be permanent'. In a particular patient the levels are usually remarkably stable, showing little fluctuation regardless of initial concentration8 13. With continued growth of the tumour and progression of the disease, the levels either remain the same or increase only slightly. This suggests that either the serum concentration is regulated in some way, or that the phase of rapidly increasing serum AFP levels occurs before the patient becomes symptomatic or the tumour clinically obvious. Occasionally, in a patient neat death the serum concentration of the protein falls precipitously8'44. As might be expected, serum AFP levels fall rapidly after resection of the tumour, and with recurrence, the globulin reappears. Serial quantitation of AFP during this period has shown that the protein reaches the characteristic level for that particular tumour three to six months after first becoming detectable41.
At present, it would seem reasonable to use the conventional, relatively insensitive methods for detecting AFP in the diagnosis of primary hepatocellular cancer, and the more sensitive techniques for following the course of the disease and assessing response to treatment.
The likely site of production of AFP in primary hepatocellular cancer is the tumour itself. The explanation for the resumption of synthesis by malignant hepatocytes is obscure. Two possible mechanisms have been considered. First, it has been suggested that with neoplastic transformation the hepatocytes dedifferentiate to a stage of development at which the AFP genome is not repressed, and production of the protein is resumed47. The second possibility is that the tumour arises from those cells which have the AFP genome in a non-repressed form1 46. With either view, the renewed production of the globulin reflects the presence of a population of hepatic parenchymal cells that is less mature than the hepatocytes which normally produce 'adult' proteins. Why some tumours synthesize and secrete AFP while others do not has not been established.
The introduction of highly sensitive methods for detecting and quantitating AFP has made meaningful epidemiological studies possible (although expensive and time consuming). Purves et a146 have measured AFP concentrations in populations in areas which carry a high risk of primary hepatocellular cancer and have found raised levels in a higher proportion of apparently normal subjects than in other populations. Elevated levels diminished in individuals who left the high-risk areas, suggesting that they may reflect exposure to environmental carcinogens. There is some experimental support for this belief. By giving carcinogens, Kroes, Williams, and Weisburger48 were able to induce AFP synthesis in rats before cancers were detectable histologically. With discontinuation of the chemical, the protein disappeared, possibly as a result of the immunological elimination of AFP-producing cells.
Alpha-fetoprotein has also been used as a screening test for early primary hepatocellular cancer in susceptible populations34'42. Unfortunately, these attempts have thus far proved unrewarding.
Other Liver Diseases
With the use of the more sensitive methods now available, raised levels of AFP have been detected in the serum of patients with various forms of liver disease other than primary tumours. Liver cell damage and regeneration are common to all of these conditions. It is not yet known whether the AFP found in these conditions is identical with that present in foetal serum and patients with primary hepatocellular cancer. Although the exact source of the protein has not been determined, it is likely that synthesis takes place in hepatocytes.
The changes occurring in acute viral hepatitis have been most fully documented. Smith49 reported that serum AFP levels increased only in patients with virus-B hepatitis, but other workers50'51 have found the concentrations to be equally elevated in both forms of the disease. Maximum concentrations have usually been noted during the recovery phase of the illness50'52, which is in keeping with the experimental observation that AFP is produced during the regeneration of hepatocytes'. Increased synthesis might then be due to retrodifferentiation of mature liver cells during regeneration to a stage at which AFP is again produced', or to proliferation or activation of those relatively undifferentiated hepatocytes that have the AFP genome in a non-repressed statel"52. In two recent studies40'51 the AFP response has been related to the serum transaminase level, used as an index of hepatic damage. While in some patients the AFP concentration increased as the transaminase level returned to normal, suggesting synthesis during regeneration, in the majority of cases AFP and transaminase levels ran parallel courses, a pattern more in keeping with an acute-phase response to liver injury, or some change directly attributable to the presence of the virus. In most patients, mild or moderate elevations of the protein occur, but in some, particularly children, high serum concentrations are reached, and AFP can then be detected by conventional methods51.
With the exception of Indian childhood cirrhosis, the changes in cirrhotic patients have been less marked. Using radioimmunoassay, Ruoslahti and Seppalai52 have found moderately high levels of the protein in only two of 13 cirrhotic patients, and AFP has rarely, if ever, been detected by conventional methods in patients with cirrhosis or chronic active hepatitis. It is possible that with long-continued or recurrent regeneration of hepatocytes 'exhaustion' of AFP synthesis occurs. Alternatively, a minimal regeneration rate may be necessary for AFP to be 'induced'. Using conventional techniques, Nayak and his associates53 found AFP in the serum of 45% of patients with Indian childhood cirrhosis. They suggested that in infants who later develop this condition, the fetal hepatocyte fails to achieve the normal adult transformation, the defect being manifest in the continuing synthesis and secretion of the globulin. A similar explanation might account for the finding by radioimmunoassay of moderately raised levels of AFP in the serum of patients with ataxia telangiectasia54. Alpha-fetoprotein has also been demonstrated in the serum of patients with tyrosinosis55. The explanation is not known, but the presence of the protein is probably related in part to the severe liver damage which occurs in these children.
Alpha-fetoprotein has been found in the serum of infants with congenital biliary atresia and neonatal hepatitis56'57'58 . The levels encountered in the latter condition are signficantly higher than in the former58, and this may be of value in the differential diagnosis between the two diseases. Apart from the mechanisms already considered with respect to acute viral hepatitis, two possible causes for AfP synthesis in these conditions have been postulated. One is that persistent deep jaundice may retard the differentiation of fetal and neonatal hepatocytes, leading to continued synthesis of the protein in large amounts. The other is that if viral infections are the cause of these diseases, the virus itself may be responsible for derepressing the AFP genome.
Tumours of Entodermal Origin
Alpha-fetoprotein has occasionally been demonstrated in the serum of patients with entodermal tumours8 1929. With the use of the more sensitive methods, this association is encountered more frequently, eg, Abelev et a159 found raised levels in 13 % and Alpert43 in 7 % of such patients. The concentrations are, however, much lower than those seen in primary hepatocellular cancer. It was initially suggested that this phenomenon could be explained by increased synthesis of the protein in rapidly regenerating hepatic tissue adjacent to secondary deposits20. However, not all patients have had hepatic metastases. Moreover, tumour tissue of non-hepatic origin implanted into the liver of an experimental animal did not result in AFP synthesis60.
With two exceptions, one with malignant lymphogranulomatosis32 and the other with a Wilm's tumour61, the primary tumours in all the patients reported have been either in the gastrointestinal tract or in organs derived from the primitive foregut. In the former group, the primary tumour has, with rare exceptions25'26, been used65'67 . As is the case in both primary hepatocellular cancer and acute hepatitis, AFP is more frequently encountered in children with these tumours than in adults55. Neither well differentiated embryonal cancers nor other types of testicular or ovarian tumours appear to share this property. Alpha-fetoprotein has occasionally been found in the serum of patients with primary mediastinal, retroperitoneal, or presacral teratocarcinomas43,68,69
Some correlation appears to exist between the presence of AFP in patients with these cancers and the degree of malignancy of the tumour, those synthesizing the globulin being more malignant and less likely to respond to treatment63. There seems also to be a relationship with the size of the tumour, and in some patients AFP could be demonstrated in the serum only after extensive metastases had occurred6i5. Serial quantitation of the protein level may be useful in following the course of the disease70, as a test of completeness of resection63, and in assessing response to therapy63'71, far more so than has been possible with primary hepatocellular cancer.
The likely site of AFP synthesis in these patients is the tumour itself. Teratocarcinomas are capable of forming dedifferentiated tissues including yolk sac and, less frequently, hepatocytes, and both have the potential to produce AFP62. Undifferentiated teratoma cells or yolk sac tissue seems the more probable origin7l 72in view of the tissue culture experiments of Kahan and Levine73, as well as the recent reports of AFP production by yolk sac carcinomas of the ovary69'71'74.
AFP in Antenatal Diagnosis
With the introduction of more sensitive techniques for measuring AFP levels, a further diagnostic use for this protein has become apparent. The normal values of AFP in amniotic fluid75'76 and in maternal serum75'77 have been established, and it has been realized that increased levels may be associated with foetal distress, intrauterine death, and severe congenital anomalies ofthe neural tube75 '76 78'79 . In the latter instances, AFP presumably gains access to the amnion through cerebrospinal fluid leakage76, while in the other circumstances, it has been suggested that the globulin is secreted into the amnion in fetal urine75'80. High maternal serum concentrations probably originate from the fetus. They may result from increased synthesis by the liver of the distressed fetus, placental leakage of fetal elements, or by way of the amniotic fluid78.
The finding of abnormally high amniotic fluid AFP levels has made early diagnosis of serious neural tube defects and termination of pregnancy possible81-83. Examination of maternal serum levels, which has the advantage of ease and safety, has been less useful, because a clear separation between normal values and those found with an abnormal or distressed fetus have not always been found84'85. 
